Literature DB >> 10818510

Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.

S Craft1, S Asthana, G Schellenberg, L Baker, M Cherrier, A A Boyt, R N Martins, M Raskind, E Peskind, S Plymate.   

Abstract

Higher fasting plasma insulin levels and reduced CSF-to-plasma insulin ratios, suggestive of insulin resistance, have been observed in patients with Alzheimer's disease (AD) who do not possess an apolipoprotein E (ApoE)-epsilon 4 allele. Insulin has also been implicated in processing of beta-amyloid and amyloid precursor protein (APP). We examined the effects of intravenous insulin administration while maintaining euglycemia on insulin-mediated glucose disposal, memory, and plasma APP in patients with AD and normal adults of varying ApoE genotypes. AD subjects without an epsilon 4 allele had significantly lower insulin-mediated glucose disposal rates than did AD patients with an epsilon 4 allele (p < 0.03) or than did normal adults without an epsilon 4 allele (p < 0.02). AD subjects without an epsilon 4 allele also showed significant memory facilitation with insulin administration (p < 0.04), whereas the AD-epsilon 4 group did not. Insulin reduced APP levels for AD patients without an ApoE epsilon 4 allele, but raised APP for AD patients with an ApoE epsilon H4 allele These results document ApoE-related differences in insulin metabolism in AD that may relate to disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818510     DOI: 10.1111/j.1749-6632.2000.tb06371.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  60 in total

Review 1.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The effect of glucose dose and fasting interval on cognitive function: a double-blind, placebo-controlled, six-way crossover study.

Authors:  Lauren Owen; Andrew B Scholey; Yvonne Finnegan; Henglong Hu; Sandra I Sünram-Lea
Journal:  Psychopharmacology (Berl)       Date:  2011-10-07       Impact factor: 4.530

Review 3.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

4.  Interactive effects of apolipoprotein E4 and diabetes risk on later myelinating white matter regions in neurologically healthy older aged adults.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Tyler A Zink; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-12-31       Impact factor: 2.035

Review 5.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 6.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

Review 7.  Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Authors:  Konstantinos Ioannis Avgerinos; Grigorios Kalaitzidis; Antonia Malli; Dimitrios Kalaitzoglou; Pavlos Gr Myserlis; Vasileios-Arsenios Lioutas
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 8.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

9.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.